mRNA vaccine treatment for advanced liver cancer

An Open, Single-center, Multiple-dose, Dose-increasing and Dose-expanding Clinical Study to Observe and Evaluate the Safety, Tolerance, Immunokinetics and Preliminary Effectiveness of ABOR2014 Injection (IPM511) in the Treatment of Advanced Hepatocellular Carcinoma

This study is testing a new mRNA vaccine to see if it can help people with advanced liver cancer who haven't responded to other treatments.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 48 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Peking Union Medical College Hospital (Academic / other)
• Drugs / interventions: prednisone
• Locations: 1 site (Beijing, Beijing)
• Trial ID: NCT05981066 on ClinicalTrials.gov

What this trial studies

This clinical study evaluates the safety, tolerability, and preliminary efficacy of the mRNA vaccine ABOR2014/IPM511 in patients with advanced hepatocellular carcinoma who have relapsed or are refractory to standard treatments. It is an open-label, single-site trial conducted at Peking Union Medical College Hospital. Participants will receive the vaccine via intramuscular injection and will be monitored for their response to the treatment. The study aims to provide insights into the potential of mRNA vaccines in treating this challenging cancer.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with advanced hepatocellular carcinoma who have failed or are intolerant to previous treatments.

Not a fit: Patients with early-stage liver cancer or those who have not yet undergone standard treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new therapeutic option for patients with advanced hepatocellular carcinoma who have limited treatment choices.

How similar studies have performed: While the use of mRNA vaccines in cancer treatment is a novel approach, preliminary studies in similar contexts have shown promising results.

Eligibility criteria

Inclusion Criteria:

1. Subjects who understand and voluntarily sign the informed consent form;
2. Male or female subjects ≥ 18 years old;
3. Patients with pathological or cytological evidence of locally advanced or hepatocellular carcinoma, who have failed or are intolerant of previous standard treatments;
4. At least one measurable lesion judged according to the RECIST version 1.1 standard.
5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 (inclusive);
6. Life expectancy ≥ 12 weeks;
7. HLA typing: A-02;
8. Laboratory tests at screening shall meet the following requirements:

   * Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L;
   * Platelet count (PLT) ≥ 90 × 10\^9/L;
   * Hemoglobin (Hb) ≥ 90 g/L;
   * Total bilirubin (TBIL) ≤ 3 × ULN;
   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN;
   * Blood creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (calculated based on Cockcroft-Gault formula) ≥ 45 mL/min;
   * International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN;
   * QTc interval (calculated based on Fridericia's formula) ≤ 450 ms for males and ≤ 470 ms for females;
9. For subjects with hepatitis B-related primary hepatocellular carcinoma (HBV-HCC) or hepatitis C-related primary hepatocellular carcinoma (HCV-HCC), those who are with the following conditions are eligible to be enrolled:

   * HBV-HCC: resolved HBV infection with concomitant antiviral therapy;
   * HCV-HCC: resolved or active HCV infection , where concomitant antiviral therapy may be given for active HCV infection;

9. For patients of childbearing potential (male or female), effective contraceptive measures shall be taken during the study treatment and within 3 months after the last dose. For women of childbearing potential, a negative serum/urine HCG test result within 7 days prior to study enrollment shall be provided.

Exclusion Criteria:

1. Known allergy to any of the components of the investigational product;
2. History of topical treatment with mRNA products or treatment with mRNA vaccines;
3. Patients with a history of major operations within 4 weeks before the first dose, have a plan of major operations during the study (at the investigator's discretion);
4. History of anti-tumor therapies within 4 weeks before the first dose;
5. History of receiving immunosuppressive drugs within 4 weeks before the first dose, except for corticosteroid nasal sprays, inhalants, and systemic prednisone at a dose of ≤ 10 mg/day or similar drugs at equivalent doses;
6. History of organ transplant, bone marrow transplant, or hematopoietic stem cell transplant;
7. History of hemorrhagic diseases such as anaphylactoid purpura, Haemophilia and aplastic anemia;
8. History of live attenuated vaccines within 30 days before the first dose;
9. Central nervous system (CNS) metastases that are symptomatic, untreated, or require continuous treatment;
10. Toxicological events (except alopecia and pigmentation) have not recovered to baseline or NCI-CTCAE v5.0 grade 0-1 after prior anti-tumor therapies;
11. History of autoimmune disorders;
12. History of immediate hypersensitivity, eczema that cannot be controlled by topical corticosteroids, or asthma;
13. Uncontrollable concomitant diseases;
14. Active infections currently requiring systemic anti-infective therapy; active pulmonary tuberculosis;
15. Known history of human immunodeficiency virus (HIV) positive or treponema pallidum positive;
16. Patients with other conditions that are not suitable for participation in the study at the discretion of the investigator.

Where this trial is running

Beijing, Beijing

• Peking Union Medical College Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing, China (Recruiting)

Study contacts

• Study coordinator: Zhao haitao, Dr

Conditions Advanced Hepatocellular Carcinoma; mRNA vaccine